Diabetic Macular Edema With Good Vision: Do You Need Treatment Right Away?
Diabetic Macular Edema With Good Vision at a Glance
Your eye doctor found swelling in the center of your retina. Your vision still tests well. For most people in this spot, watching closely is a reasonable first choice, and your eye doctor makes that call with you. A large trial tested three plans in eyes like yours. All of them read 20/25 or better. One group got shots in the eye at once. One got laser. The third was watched, and treated only if sight dropped. After two years, the share that lost at least 5 letters was 16 of every 100 with shots, 17 of every 100 with laser, and 19 of every 100 with watching. That gap was small enough to be chance1.
Watching is not doing nothing. It means checks on a set schedule. Care starts the week your vision slips.
Two labels drive this choice. The first is where the fluid sits. Center-involved means it reaches the middle of the macula, the small patch of retina you read with. The second is how you read the chart today, which here means 20/25 or better. The American Academy of Ophthalmology's practice guidelines follow that line. In eyes with good visual acuity and center-involved swelling, treatment may reasonably be deferred until acuity is affected, meaning 20/30 or worse. Anti-VEGF injections are effective once vision has dropped2.
Three steps matter more than the treat-or-wait question. Book your follow-up before you leave the office, because the plan rests on not missing checks. Ask who owns your monitoring. Then turn the same energy toward your blood sugar, blood pressure, and cholesterol.
What Diabetic Macular Edema Is and Why It Can Be Silent
The retina lines the back of the eye and senses light. The macula is its center. Macular edema is swelling in the macula caused by leaking retinal blood vessels. It can blur vision, make lines look wavy, make an object look like a different size in each eye, and make colors look faded3. In diabetes, years of high blood sugar weaken these tiny vessels until they seep.
Picture waterlogged carpet, not a tear. The layers still work. They are just lifted apart by fluid, which is why sight can hold up early.
About 1 in 15 people with diabetes develops diabetic macular edema, in which retinal blood vessels leak fluid into the macula4. That makes it uncommon overall, and familiar to every retina clinic.
Being found now, while you still read 20/25 or better, is a better starting point than being found later. It makes monitoring a real option.
An eye chart measures one thing: the smallest sharp black letters you can name in good light. Retinal tissue can hold fluid and still resolve them. Some people notice nothing, and the swelling shows up only on a scan.
A study inside the same trial measured faint grey letters in 387 people. The change from the start to 2 years did not differ between the injection, laser, and watching groups. The authors noted the study might have been too small to detect a difference that mattered5. So that study found no hidden loss, and it could not rule out a small one. That is why scans, not the chart alone, drive monitoring.
What Causes the Swelling and What Raises Your Risk
The root problem is diabetic retinopathy, the harm high blood sugar does to retinal vessels over years. Weak vessel walls form tiny bulges and leak fluid and fats. When that lands in the macula, you get this swelling.
Later-stage diabetic retinopathy can also bleed into the gel inside the eye, causing dark floating spots or cobweb streaks. It can form scar tissue that pulls the retina away from the back of the eye4. Those are separate, far less common problems with their own warning signs, listed later on this page.
The numbers that drive diabetes complications drive this one. The American Diabetes Association recommends strategies that help people reach glycemic goals, in order to lower the risk of diabetic retinopathy or slow it down. That carries an A-level rating. Blood pressure and lipid goals carry the same aim6. Managing diabetes helps prevent or delay vision loss4.
None of that promises your swelling will clear. It does mean this work aims at the same target as your eye care, and it is the part you control.
How long you have had diabetes matters. So does how far your retinopathy has already gone. In a look back at 56 untreated eyes with center-involving swelling and vision of 20/25 or better, followed about 5 years, 42 of the 56 lost some vision at some point. Eyes with worse retinopathy at the start tended to fare worse7. That was one small single-center review of eyes with no set monitoring plan. Read it as a caution about drifting out of care, not a forecast for you.
Symptoms to Watch For and How to Check Yourself at Home
Symptoms show up in the center of vision, not the edges. Reading slows. Small print smudges. Faces across a table lose detail. Many people say they need more light than before.
These changes are usually gradual, and they do not mean you missed your chance. They are the cue to move your appointment up.
Two patterns slip past people. The first is one-eye change, because the stronger eye covers for the weaker one. The second is bending rather than blur, such as a doorframe that kinks. Wavy vision, and objects looking like different sizes in each eye, are known features of macular swelling3.
Home checks close the gap between visits. Once a week, cover one eye and look at something with straight lines, such as a window frame. Note any line that bends or patch that looks blank. Then swap eyes. Many clinics hand out an Amsler grid, a printed square of fine lines, for this.
Write down what you see, even when normal. A record makes a real change obvious, and home checks do not replace scans.
How Diabetic Macular Edema Is Diagnosed and Tracked
Diagnosis starts with drops that widen the pupil so your doctor can see the retina. A dilated eye exam, optical coherence tomography imaging, and sometimes a fluorescein angiogram are the tests used to find macular swelling3. The exam also grades how far your retinopathy has gone, which feeds the treat-or-watch choice.
Plan for a few blurry hours after, and bring sunglasses or a driver.
Optical coherence tomography, or OCT, is a quick light-based scan. It shows a cross-section of your retina. Nothing touches your eye and it takes a couple of minutes. It shows where fluid sits and gives a central thickness reading your doctor tracks over time.
That number is why monitoring beats a chart reading alone. Rising thickness can shorten your follow-up interval even when your vision has not changed.
In this test, a dye goes into a vein in your arm. A camera photographs it moving through the retinal vessels, mapping which ones leak. It is one of the standard tests used to look at macular swelling3. It is not needed at every visit, and many people never have one.
There is no single fixed interval for this situation. Follow-up is closer than a routine yearly diabetic eye check, and your OCT and chart reading set the spacing, not the calendar alone. Ask your doctor for your interval in writing.
For baseline diabetic eye screening, the American Academy of Ophthalmology advises annual screening starting 5 years after the onset of type 1 diabetes. For type 2 diabetes, screening should start promptly at diagnosis and repeat at least yearly. People who are pregnant with diabetes should be examined early and followed closely, because retinopathy can move quickly8.
Treat Now or Watch Closely: What the Research Found
This question was tested head-on rather than left to opinion. Protocol V enrolled 702 adults with diabetes at 91 sites in the United States and Canada. Each had one eye with center-involved swelling and vision of 20/25 or better. Eyes were assigned at random to immediate aflibercept injections, to laser, or to observation. Laser and observation eyes started aflibercept if vision worsened1.
The design is what makes the answer usable. Everyone was watched closely, and treatment was on hand the moment sight dropped.
At two years, 16 of every 100 eyes lost at least 5 letters in the injection group, 17 of every 100 in the laser group, and 19 of every 100 in the observation group. The differences were not statistically significant1. The table sets the numbers side by side.
| Starting plan | Lost 5 or more letters at 2 years | Got injections in those 2 years |
|---|---|---|
| Injections right away | 16 of every 100 eyes | All, by design |
| Laser first | 17 of every 100 eyes | 25 of every 100 eyes |
| Watch closely | 19 of every 100 eyes | 34 of every 100 eyes |
In Protocol V, 34 of every 100 eyes assigned to observation and 25 of every 100 assigned to laser went on to receive aflibercept during follow-up1. Turned around, about two of every three watched eyes got through two years without an injection.
Neither number predicts your eye. They are the odds a room of similar people faced, and they are why watching is a choice you revisit.
The American Academy of Ophthalmology states that with good visual acuity and center-involved swelling, treatment may reasonably be deferred until acuity is affected at 20/30 or worse. Anti-VEGF injections are effective once vision has dropped2. In practice the trigger is a measured fall in your chart vision, sometimes with a worsening OCT.
That is why this is called deferring, not declining. Treatment is held ready and started on a defined signal.
Your Treatment Options and What Each One Involves
Anti-VEGF drugs block the signal that makes retinal vessels leak. They are given into the gel of the eye after numbing drops. The FDA-approved label for aflibercept (Eylea) lists diabetic macular edema among its approved uses. The dose is 2 mg by intravitreal injection every 4 weeks for the first 5 injections, then once every 8 weeks. Listed contraindications are eye or nearby infection, active inflammation inside the eye, and hypersensitivity to aflibercept9.
Many people describe pressure rather than sharp pain. The schedule, not the needle, is what most find hardest.
Anti-VEGF drugs used for this condition include ranibizumab, aflibercept, bevacizumab, faricimab, and brolucizumab. Steroids placed inside the eye, such as dexamethasone, fluocinolone acetonide, and triamcinolone acetonide, are also used, though usually not first, because of cataract and glaucoma risk10. The FDA-approved label for bevacizumab (Avastin) lists only cancer uses and no eye use, so giving it inside the eye for a retinal condition is off-label11. It is widely used that way, often on cost.
Systemic control is not a substitute for eye treatment. Reaching glycemic, blood pressure, and lipid goals is advised to lower the risk of diabetic retinopathy or slow its progression6.
Ask your diabetes team for your current A1c and blood pressure, and what targets they want.
Risks, Burden, and a Realistic Outlook
The honest risk is that vision drops between visits, or that you drift out of follow-up. In that review of 56 untreated eyes with good starting vision followed about 5 years, 42 of the 56 lost some vision at some point7. Those eyes had no set monitoring plan with treatment triggered at the first drop.
The counterweight is the trial. With close monitoring and treatment on a defined trigger, two-year vision was similar whether eyes started with injections, laser, or observation1. Keeping appointments is what makes watching safe.
Injections carry small but real risks. In a review pooling eight studies, 87 cases of endophthalmitis, a serious infection inside the eye, occurred among 276,774 injections. That is roughly 3 in every 10,000 injections12. Labeled warnings for aflibercept also include retinal detachment, sharp rises in eye pressure within 60 minutes of an injection, and arterial blood clot events9.
Eye infections are treated urgently. That is why clinics ask you to call the same day about a painful, red, or suddenly blurry eye after an injection. The burden most people feel is different: repeat visits, travel, and copays.
Everything here describes groups. The 702-person trial was built to compare how many eyes in each group lost at least 5 letters over two years, not to forecast what one eye will do1. Your eye may sit anywhere inside those groups. No page and no doctor can say in advance which.
If you keep the schedule, a drop is likely to be caught while treatment still has good evidence behind it. That is reason to feel steady rather than rushed.
When to Call Your Eye Doctor
Macular swelling itself does not usually call for same-day care. A few other symptoms in a diabetic eye do. Call your eye doctor or seek urgent eye care the same day for any of these:
- A sudden shower of new floaters, or a burst of dark spots or cobweb streaks
- A curtain, shadow, or dark veil moving across part of your vision
- Sudden loss of vision in one eye, or a large drop over hours to a day
- Flashes of light that are new and repeated
- A painful, red, or suddenly blurry eye in the days after an eye injection
These can signal bleeding into the gel of the eye, or a retina pulled away from the back of the eye4. Timing matters for a detachment. In a pooled analysis of 20 studies covering 1,929 patients, eyes with the macula still attached that were repaired within 24 hours of presentation had better final vision than those repaired later13. Most such calls turn out to be something milder. Making the call costs you an afternoon.
Some changes are not emergencies, and should not wait for your next visit either. Call within a few days if reading has become harder, if straight lines look bent on your home check, or if one eye seems worse than last time.
These are what monitoring exists to catch. A measured drop in acuity is the point at which guidelines advise starting anti-VEGF treatment for center-involved swelling2. An early call moves you into treatment on schedule.
Center-involved swelling is usually managed by an ophthalmologist, often a retina specialist, since that is who gives injections and reads the scans. Optometrists often handle diabetic eye screening, interim monitoring, and the referral.
Ask one plain question: who tracks my OCT, and who do I call if my vision changes? A name and a phone number turn a watching plan into a safe one.
Common Questions About Diabetic Macular Edema With Good Vision
Not measurably over two years, based on the best trial in this exact situation. Eyes with center-involved swelling and 20/25 or better vision that were watched closely ended up much like eyes treated at once. A faint-contrast letter study inside that trial also found no significant difference between the groups. The swelling is a real finding that needs tracking, and today it is not costing you letters.
That is the planned path, not a failure. In the trial, watched eyes started injections when vision dropped, and their two-year results were similar to eyes injected from the start. The condition for that is close follow-up, so a drop is found in weeks rather than months. The American Academy of Ophthalmology advises starting treatment once acuity reaches 20/30 or worse.
Swelling can settle without treatment in some eyes. In the trial, about two of every three eyes assigned to observation went two years without an injection. That is not the same as the fluid clearing in all of them, and it is not something to count on for your eye. It is why doctors track the OCT thickness number instead of assuming either direction.
More often than a routine yearly diabetic eye exam. Your doctor sets the interval from your chart vision and your OCT scan. Intervals typically shorten when the retina thickens and lengthen when it stays stable. Ask at each visit when you are due back, and what would make you come sooner.
No. Eye treatment and diabetes control run at the same time, and injections are not held back while you work on your A1c. Reaching glycemic, blood pressure, and lipid goals is advised to lower the risk of retinopathy or slow it. That work is worth doing on its own terms, not as a precondition for eye care.
Many people describe pressure and a brief sting rather than sharp pain. Numbing drops or gel come first, and the injection takes seconds. Grittiness or a small red patch on the white of the eye for a day or two is common. Pain that starts or worsens afterward is not expected, and it is a reason to call the same day.
More Questions About Monitoring, Treatment, and Daily Life
It performed similarly in the trial. At two years, 17 of every 100 laser eyes lost at least 5 letters, against 16 with injections and 19 with observation. About 25 of every 100 laser eyes still needed injections in that window. Laser is usually one session, not a repeating schedule. Ask your retina specialist whether your leakage pattern suits it.
Generally yes, since your vision currently meets the standard that defines this situation. Driving rules depend on your state's vision requirements and on both eyes together, so confirm with your eye doctor. Report new trouble with night driving, glare, or road signs, because those can appear before the chart changes.
Not necessarily. Both eyes share the same diabetes and the same vessel risk, so both are examined and scanned at your visits. Many people have swelling in one eye only for years. The response is the same either way: keep the schedule for both eyes, and work on your systemic numbers.
Plan for a course rather than a single shot, though not necessarily forever. The labeled aflibercept regimen is every 4 weeks for the first 5 injections, then once every 8 weeks. Doctors adjust from there based on how the retina responds. Some people space visits out over time, and others need ongoing treatment.
- Is my swelling center-involved, and what is my OCT central thickness number?
- What is my visual acuity today, and what reading would trigger treatment?
- How often do you want to see me, and what should make me call sooner?
- How advanced is my diabetic retinopathy, and does that change the plan?
- If we start treatment, which drug would you use, and what will it cost me?
- Who tracks my scans between visits, and what number do I call?
- Should my other eye be monitored on the same schedule?
- What A1c and blood pressure targets should I work toward?
- Baker CW et al., JAMA (DRCR Retina Network Protocol V), 91 US and Canadian sites (2019). Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.
- American Academy of Ophthalmology, Preferred Practice Pattern (Retina/Vitreous Panel) (2024). Diabetic Retinopathy Preferred Practice Pattern.
- National Eye Institute, National Institutes of Health (2025). Macular Edema.
- National Eye Institute, National Institutes of Health (2025). Diabetic Retinopathy.
- DRCR Retina Network, Translational Vision Science and Technology (2021). Effect of Initial Aflibercept, Laser, or Observation on Low-Contrast Visual Acuity in Eyes With Diabetic Macular Edema and Good Vision: Ancillary Study Within a Randomized Clinical Trial.
- American Diabetes Association, Diabetes Care (2026). 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes 2026.
- Lent-Schochet D et al., Retina (retrospective cohort, single academic center) (2021). Natural History and Predictors of Vision Loss in Eyes with Diabetic Macular Edema and Good Initial Visual Acuity.
- American Academy of Ophthalmology, Preferred Practice Pattern (Retina/Vitreous Panel) (2024). Diabetic Retinopathy Preferred Practice Pattern: examination schedule recommendations.
- US Food and Drug Administration approved label, Regeneron Pharmaceuticals (via DailyMed) (2024). EYLEA (aflibercept) injection, for intravitreal use: US prescribing information.
- Tatsumi T, International Journal of Molecular Sciences (review) (2023). Current Treatments for Diabetic Macular Edema.
- US Food and Drug Administration approved label, Genentech (via DailyMed) (2024). AVASTIN (bevacizumab) injection, for intravenous use: US prescribing information.
- Bande MF et al., Scientific Reports (2017). Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: a systematic review and meta-analysis.
- Sothivannan A et al., American Journal of Ophthalmology (2022). Impact of the Time to Surgery on Visual Outcomes for Rhegmatogenous Retinal Detachment Repair: A Meta-Analysis.